Benzinga | May 6, 2021 07:43AM EDT

Biocryst Pharmaceuticals Q1 EPS $(0.36) Misses $(0.27) Estimate, Sales $19.10M Beat $8.89M Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 50 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $19.10 million which beat the analyst consensus estimate of $8.89 million by 114.85 percent. This is a 296.02 percent increase over sales of $4.82 million the same period last year.